These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20547791)

  • 21. Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.
    Lai CC; Chen CC; Chuang YC; Tang HJ
    Sci Rep; 2017 Jan; 7():41758. PubMed ID: 28139739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.
    Tenover FC; Lancaster MV; Hill BC; Steward CD; Stocker SA; Hancock GA; O'Hara CM; McAllister SK; Clark NC; Hiramatsu K
    J Clin Microbiol; 1998 Apr; 36(4):1020-7. PubMed ID: 9542929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
    Richter SS; Satola SW; Crispell EK; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Diekema DJ; Doern GV
    J Clin Microbiol; 2011 Dec; 49(12):4203-7. PubMed ID: 21976769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
    Tabe Y; Nakamura A; Igari J
    J Infect Chemother; 2001 Sep; 7(3):142-7. PubMed ID: 11810575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.
    Satola SW; Farley MM; Anderson KF; Patel JB
    J Clin Microbiol; 2011 Jan; 49(1):177-83. PubMed ID: 21048008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.
    Sahm DF; Kissinger J; Gilmore MS; Murray PR; Mulder R; Solliday J; Clarke B
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1588-91. PubMed ID: 2554802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A; Cassone M; Monaco M; Tarasi D; Pompeo ME; Venditti M
    J Chemother; 2003 Jun; 15(3):239-43. PubMed ID: 12868549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycopeptide and oxacillin activity against Staphylococcus aureus isolates at a tertiary care center in Lebanon.
    Kanj SS; Ghaleb PA; Araj GF
    J Med Liban; 2004; 52(1):8-12. PubMed ID: 15881695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies.
    Pankuch GA; Lin G; Hoellman DB; Good CE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2006 May; 50(5):1727-30. PubMed ID: 16641442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.
    Biavasco F; Vignaroli C; Lazzarini R; Varaldo PE
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3122-6. PubMed ID: 11036034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers.
    Jones RN; Barry AL; Gardiner RV; Packer RR
    Diagn Microbiol Infect Dis; 1989; 12(5):385-94. PubMed ID: 2533050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus.
    Swenson JM; Anderson KF; Lonsway DR; Thompson A; McAllister SK; Limbago BM; Carey RB; Tenover FC; Patel JB
    J Clin Microbiol; 2009 Jul; 47(7):2013-7. PubMed ID: 19420170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
    Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
    Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
    Çıkman A; Aydın M; Gülhan B; Parlak M; Gültepe B; Kalaycı Y; Bayındır Bilmen F; Solmaz S; Özekinci T
    Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs.
    Vedel G; Leruez M; Lémann F; Hraoui E; Ratovohery D
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):820-2. PubMed ID: 2150815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Pistella E; Falcone M; Baiocchi P; Pompeo ME; Pierciaccante A; Penni A; Venditti M
    Infez Med; 2005 Jun; 13(2):97-102. PubMed ID: 16220029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance.
    Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López-Fabal F; Gómez M;
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):373-9. PubMed ID: 21683269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.
    Guenthner SH; Wenzel RP
    Antimicrob Agents Chemother; 1984 Aug; 26(2):268-9. PubMed ID: 6237606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.